Angiogenesis in Glioblastoma Multiforme: Navigating the Maze

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Angiogenesis in Glioblastoma Multiforme: Navigating the Maze



Anti-Cancer Agents in Medicinal Chemistry, 11(8): 712-718.

Author(s): Amanda G. Linkous and Eugenia M Yazlovitskaya.

Affiliation: Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, C3210 Medical Center North 1161 21st Ave South, Nashville, TN 37232.

Abstract

Blood vessel formation is a fundamental process that occurs during both normal and pathologic periods of tissue growth. In aggressive malignancies such as glioblastoma multiforme (GBM), vascularization is often excessive and facilitates tumor progression. In an attempt to maintain tumors in a state of quiescence, multiple anti-angiogenic agents have been developed. Although several angiogenesis inhibitors have produced enhanced clinical benefits in GBM, many of these pharmacologic agents result in transitory initial response phases followed by evasive tumor resistance. Thus, a significant need exists for the discovery of novel and effective anti-angiogenic therapies. The development of new molecular-targeted therapeutic strategies is often complicated by the complexity of angiogenic signal transduction. Due to the labyrinthine nature of these signaling pathways, increased production of other angiogenic factors may compensate for the inhibition of key vascular targets like vascular endothelial growth factor (VEGF). Such compensatory mechanisms facilitate vascularization and allow tumor growth to proceed even in the presence of anti-angiogenic agents. This review presents the challenges of targeting the intricate vascular network of GBM and discusses the clinical implications for recent advancements in targeted anti-angiogenic drug therapy.

Keywords:

Angiogenesis, anti-angiogenic agents, drug resistance, glioblastoma multiforme (GBM), signal transduction, targeted drug therapy, tumor vascularization, vascular network, pro-angiogenic factors, magnetic resonance imaging.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 11
Issue Number: 8
First Page: 712
Last Page: 718
Page Count: 7
DOI: 10.2174/187152011797378643
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science